Analysis of Donor Biopsy Tissue Samples at the Time of Kidney Transplant
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to see if substances measured in a small piece of the donor organ predicts how well the organ will function in the recipient after transplant. We will be testing blood, urine, and biopsy tissue samples in this study. The research team will be looking at different risk factors in the donor organ that predict how well the kidney will do in the recipient.
| Condition | Intervention |
|---|---|
|
Kidney Transplantation |
Procedure: Kidney Biopsy |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Basic Science |
| Official Title: | mRNA and microRNA Profiles in Renal Transplant at the Time of Organ Reperfusion |
- Primary endpoint for Aim 1 is the incidence of early organ dysfunction, defined by standard criteria for each organ defined as the need for dialysis within 7 days after transplant [ Time Frame: 7 days ] [ Designated as safety issue: No ]
- Primary endpoint for Aim 2 is the incidence of biopsy proven acute cellular rejection within the first 12 months after transplant [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Serum Creatinine [ Time Frame: 24 months ] [ Designated as safety issue: No ]Correlation between proinflammatory mediators at the time of transplantation and renal function as measured by serum creatinine
- Incidence of chronic allograft nephropathy [ Time Frame: 24 months ] [ Designated as safety issue: No ]Correlation between proinflammatory mediators at the time of transplantation and incidence of chronic allograft nephropathy
| Estimated Enrollment: | 120 |
| Study Start Date: | September 2010 |
| Estimated Primary Completion Date: | December 2015 (Final data collection date for primary outcome measure) |
-
Procedure: Kidney Biopsy
Background:
Early post-transplant kidney function can be attributed to inherent donor characteristics, damage from storage, and perioperative events and recipients factors. The incidence of severe injury to the transplant kidneys is 10-25% in the early post-transplant period. In addition, milder forms of early transplant kidney injury can impact on long term allograft function. Severe transplant kidney injury in the immediate post-transplant period has been hypothesized to be associated with higher rates of rejection.
Hypothesis:
In the current investigation, we would like to test the hypotheses that 1) mRNA and microRNA expression of proinflammatory genes in donor tissues is a risk factor for development of early kidney transplant dysfunction and 2) early inflammatory mRNA and microRNA expression in the allograft is associated with subsequent activation of cell mediated immunity as evidenced by increased incidence of acute rejection episodes and increased expression of cell mediated immunity genes during the first year post-transplant.
Aims:
Aim 1: Test the association between proinflammatory mRNA and microRNA expression in donor samples and subsequent development of early organ dysfunction in the immediate period following transplantation.
Aim 2: Test the association of mRNA and microRNA expression of proinflammatory mediators in the transplanted organ in the immediate pre and post-reperfusion period with subsequent incidence of acute rejection and expression of genes involved in cell mediated immunity.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Males and females <80 years of age for kidney
- Recipients of single abdominal organ transplant
- Ability to provide written informed consent
- Donor blood and kidney biopsy tissues specimens are collected at the time of transplantation
Exclusion Criteria:
- Need for combined organ transplantation.
- Inability or unwillingness of a participant or legal guardian to provide written informed consent
- Clinical evidence of systemic bacterial infection in the recipient at the time of transplantation
Contacts and Locations| United States, New York | |
| Weill Cornell Medical College | Recruiting |
| New York, New York, United States, 10065 | |
| Contact: David B Leeser, MD 212-746-5330 dbl9004@med.cornell.edu | |
| Principal Investigator: David B Leeser, MD | |
More Information
No publications provided
| Responsible Party: | David B. Leeser, Weill Cornell Medical College |
| ClinicalTrials.gov Identifier: | NCT01271465 History of Changes |
| Other Study ID Numbers: | 1004010988 |
| Study First Received: | January 5, 2011 |
| Last Updated: | January 5, 2011 |
| Health Authority: | United States: Institutional Review Board |
ClinicalTrials.gov processed this record on May 23, 2013